Financial Performance - For the three-month period ended March 31, 2023, the net loss was $32.5 million, compared to a net loss of $34.8 million for the same period in 2022, representing a 6.5% improvement [9]. - Total comprehensive loss for the three-month period ended March 31, 2023, was $31.4 million, compared to a total comprehensive loss of $37.4 million for the same period in 2022, indicating a 16.5% reduction [9]. - Calyxt incurred a net loss of $5.4 million for the three months ended March 31, 2023, and used $2.0 million of cash for operating activities during the same period [338]. Cash Flow and Liquidity - Net cash flows used in operating activities for the three-month period ended March 31, 2023, were $28.3 million, an improvement from $36.6 million used in the same period in 2022, reflecting a 22.5% decrease in cash outflow [331]. - As of March 31, 2023, Cellectis, excluding Calyxt, had cash and cash equivalents of $83.5 million, sufficient to continue operations for at least twelve months [336]. - Cellectis expects cash flow from operations, government funding, and a €40.0 million finance contract with the European Investment Bank to support operations into the third quarter of 2024 [336]. - Calyxt has received $1.0 million of Interim Funding from Cibus as of March 31, 2023, with an additional $0.5 million received subsequently [340]. Going Concern and Regulatory Approval - Cellectis faces substantial doubt regarding Calyxt's ability to continue as a going concern for a period of 12 months or more from the filing date of its quarterly report [342]. - The company anticipates that it will not generate significant revenues from product sales until regulatory approval is obtained for its therapeutic product candidates [335]. Financial Reporting Adjustments - The company has made adjustments in its financial reporting to reflect discontinued operations, impacting the overall financial results presented [8].

Product Development - Cellectis will present updated preclinical data on its product candidate UCARTMUC1 for solid tumors at the AACR 2023, highlighting its potential for patients with high unmet medical needs[3] - The company developed multiplexed gene editing using TALEN® technology to enhance CAR T-cell efficacy while maintaining safety in hostile tumor microenvironments[4] - Cellectis is pioneering off-the-shelf, ready-to-use gene-edited CAR T-cells, leveraging over 22 years of experience in gene editing[5] - The therapeutic target MUC1 is overexpressed in a significant number of triple-negative breast cancer (TNBC) patients, making it a promising target for CAR T-cell therapy[8] - The presentation will explore the benefits of variable delivery routes and molecular armoring to improve the efficacy of MUC1-CAR T-cells[9] - Cellectis utilizes an allogeneic approach for CAR-T immunotherapies, aiming to address the challenges posed by the tumor microenvironment[5] - The company is committed to developing life-changing product candidates to treat diseases with unmet medical needs[5] Company Information - Cellectis' headquarters are located in Paris, France, with additional locations in New York and Raleigh, North Carolina[5] - The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS)[5] Risks and Uncertainties - Forward-looking statements indicate potential risks and uncertainties related to product development and cash runway[6]

(Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Date of event requiring this shell company report France (Jurisdiction of incorporation or organization) * Not for trading, but only in connection with the registration of the American Depositary Shares. Indicate the number of outstanding shares of common stock as of the close of the period covered by the annual report. Indicate by check mark whether the reg ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Mark Frattini - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Gena Wang - Barclays Andrea Tan - Goldman Sachs Jack Allen - Baird Hartaj Singh - Oppenheimer & Company David Dai - SMBC Yanan Zhu - Wells Fargo Securities Brooke Schuster - William Blair Silvan Tuer ...

Allogene is developing ALLO-647, its proprietary anti-CD52 monoclonal antibody intended to enable expansion and persistence of AlloCAR T product candidates, including ALLO-501A. Allogene expects that the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen, will be open to enrollment early in the second quarter. ALLO-316, Allogene's first AlloCAR T candidate for solid tumors, targets CD70, an antigen expressed on clear cell renal cell carcinoma (RCC) and ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Operator Company Participants | --- | |------------------------------------------| | | | Arthur Stril - Chief Business Officer | | Andre Choulika - Chief Executive Officer | | Mark Frattini - Chief Medical Officer | | Bing Wang - Chief Financial Officer | | Conference Call Participants | | Gena Wang - Barclays | | Jack Allen - Baird | | Yigal Nochomovitz - Citigroup | | Salveen Richter - Goldman Sachs | | David Dai - S ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month period ended September 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars mean U.S. dollars and all refe ...

Cellectis S.A. (NASDAQ:CLLS) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Ashiq Mubarack - Citi Hartaj Singh - Oppenheimer Jack Allen - Baird David Dai - SMBC Silvan Tuerkcan - JMP Securities Nicolas Abbott - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis Second Quarter 2020 Earnings ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-months periods ended June 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars mean U.S. dollars and all referenc ...

| --- | --- | --- | --- | |----------------------------------------|-------|-------|-------| | | | | | | | | | | | Commitment to a Cure | | | | | | | | | | Corporate Presentation May 2022 | | | | | | | | | | NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA | | | | | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...